Pick 2–10 funds, stocks or ETFs to see their returns, risk, costs and highlights on one page
| Fund | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ELVN | +190.78% | +7.08% | +14.00% | −2.67% | −16.70% | +4.19% | +107.80% | +307.46% | +206.71% | +39.07% |
| TBIOTECH | +8.05% | +2.62% | +7.43% | −1.39% | −9.98% | +3.24% | +12.30% | +90.52% | +38.47% | +49.18% |
| DAOL-GIHEALTH | −1.74% | −0.14% | +4.23% | −1.34% | −6.86% | +4.63% | −0.27% | −2.68% | −44.09% | −42.48% |
| BCAP-XHEALTH | +20.18% | +1.90% | +5.53% | +0.43% | +6.60% | +23.32% | +15.56% | +26.68% | −28.58% | −25.58% |
* Fewer than 12 months: the year the fund started reporting NAV, or the current year
Counts only the top holdings with available data, not the whole portfolio · Pick a pair below for details
Excludes ELVN: money market or bond funds, or no holdings data yet
| TBIOTECH | DAOL-GIHEALTH | |
|---|---|---|
| Held by both | ||
 argenx | 4.33% | 4.28% |
 Madrigal Pharmaceuticals | 4.40% | 2.99% |
 Insmed | 4.06% | 2.88% |
| Only in TBIOTECH | ||
 Amgen | 4.78% | N/A |
 Alnylam Pharmaceuticals | 4.01% | N/A |
 Rhythm Pharmaceuticals | 3.99% | N/A |
 Xenon Pharmaceuticals | 3.85% | N/A |
| Only in DAOL-GIHEALTH | ||
 Gilead Sciences | N/A | 4.79% |
 Revolution Medicines | N/A | 4.28% |
 Praxis Precision | N/A | 3.71% |
 Travere Therapeutics | N/A | 3.61% |
30 Dec 2025 → 28 Oct 2026
| Fund | Return per year | Volatility per year | Sharpe |
|---|---|---|---|
| ELVN | +190.78% | 79.69% | 2.39 |
| BCAP-XHEALTH | +20.18% | 19.56% | 1.03 |
| TBIOTECH | +8.05% | 26.21% | 0.31 |
| DAOL-GIHEALTH | −1.74% | 18.54% | −0.09 |
Sharpe here = annual return ÷ annual volatility, without deducting the risk-free rate, calculated from NAV over the selected period · Periods shorter than 1 year use the cumulative return instead of the annual return
| Drag a column header to reorder | ELVN | TBIOTECH | DAOL-GIHEALTH | BCAP-XHEALTH |
|---|---|---|---|---|
Fund details | ||||
| Fund size | N/A | 753 million | 75.01 million | 470 million |
| Inception date | N/A | 12 Mar 2020 | 28 May 2020 | 14 May 2021 |
| Master fund | N/A | กองทุน Polar Capital Funds plc - Biotechnology | Janus Henderson Horizon Biotechnology Fund | กองทุนที่ลงทุนหลายกอง |
| Dividend policy | N/A | Does not pay | Does not pay | Does not pay |
Risk and currency hedging | ||||
| Risk level | N/A | 7 | 7 | 6 |
| Hedging policy | N/A | Hedged at the manager's discretion | Hedged at the manager's discretion | Hedged at the manager's discretion |
| Share hedged | N/A | 90.18% | 77.55% | N/A |
Minimum purchase and redemption | ||||
| First purchase | N/A | 1,000 THB | 1 THB | 500 THB |
| Subsequent purchase | N/A | 1,000 THB | 1 THB | 500 THB |
| Redemption (amount) | N/A | No minimum | No minimum | No minimum |
| Redemption (units) | N/A | No minimum | No minimum | No minimum |
| Balance (amount) | N/A | No minimum | No minimum | No minimum |
| Balance (units) | N/A | No minimum | 100 units | No minimum |
Order cut-off and redemption payment | ||||
| Buy before | N/A | 15:30 | 15:00 | 15:30 |
| Redeem before | N/A | 15:30 | 15:00 | 15:30 |
| Redemption paid | N/A | T+5 | T+4 | T+3 |
